Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate

Cancer Letters

Volumn 253, Issue 1, 2007, Pages 89-96

  Nakajima, Hiroo ^a   Magae, Junji ^b   Tsuruga, Mie ^b   Sakaguchi, Koichi ^a   Fujiwara, Ikuya ^a   Mizuta, Mitsuhiko ^a   Sawai, Kiyoshi ^a   Yamagishi, Hisakazu ^a   Mizuta, Naruhiko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b INSTITUTE OF RESEARCH AND INNOVATION   (Japan)

Author keywords

Apoptosis; Bax; Bcl 2; Breast cancer; Farnesylation; YM529

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 8; CASPASE 9; CYTOCHROME C; INCADRONIC ACID; MEVALONIC ACID; MINODRONIC ACID; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BREAST NEOPLASMS; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; MEVALONIC ACID; MITOCHONDRIA; POLYISOPRENYL PHOSPHATES; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 34249906760     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.008     Document Type: Article

References (44)

1. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
2. Susin S.A., Lorenzo H.K., Zamzami N., Morzo I., Snow B.E., Brothers G.M., Mongion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aeberold R., Siderouski D.P., and Penninger J.M. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
3. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
4. Tsujimoto Y., and Shimizu S. The voltage-dependent anion channel: an essential player in apoptosis. Biochemie 84 (2002) 187-193
5. Rostovtseva T.K., Antonson B., Suzuki M., Youle R.J., Colombini M., and Bezrukov M. Bid, but not Bax, regulates VDAC channels. J. Biol. Chem. 279 (2004) 13575-13583
6. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-565
7. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., and Peter M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14 (1995) 5579-5588
8. Medema J.P., Scaffidi C., Kischkel F.C., Shevchenko A., Mann M., Krammer P.H., and Peter M.E. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16 (1997) 2794-2804
9. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
10. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
11. Fulda S., Meyer E., Friesen C., Susin S.A., Kroemer G., and Debatin K.M. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20 (2001) 1063-1075
12. Allred D.C., Harvey J.M., Berardo M., and Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11 (1998) 155-168
13. Boonekamp P.M., van der Wee-Pals L.J., van Wijk-van Lennep M.M., Thesing C.W., and Bijvoet O.L. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1 (1986) 27-39
14. Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 10 (1998) 80-100
15. Lowik C.W., van der Pluijm G., van der Wee-Pals L.J., van Treslong-De Groot H.B., and Bijvoet O.L. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J. Bone Miner. Res. 3 (1988) 185-192
16. Hughes D.E., MacDonald B.R., Russell R.G., and Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83 (1989) 1930-1935
17. Kanis J.A., Powles T., Paterson A.H., McCloskey E.V., and Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19 (1996) 663-667
18. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., and Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10 (1995) 1478-1487
19. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., Mundy G.R., and Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55 (1995) 3551-3557
20. Selander K.S., Monkkonen J., Karhukorpi E.K., Harkonen P., Hannuniemi R., and Vaananen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50 (1996) 1127-1138
21. Yoneda T., Michigami T., Yi B., Williams P.J., Niewolna M., and Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88 (2000) 2979-2988
22. Hiraga T., Williams P.J., Mundy G.R., and Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61 (2001) 4418-4424
23. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., and Clezardin P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57 (1997) 3890-3894
24. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., and Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82 (2000) 1459-1468
25. Fromigue O., Lagneaux L., and Body J.J. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15 (2000) 2211-2221
26. Senaratne S.G., Mansi J.L., and Colston K.W. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer 86 (2002) 1479-1486
27. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13 (1998) 581-589
28. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., and Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58 (1998) 5294-5297
29. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 9 (2003) 2643-2658
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65 (1983) 55-63
31. Gerlier D., and Thomasset N. Use of MTT colorimetric assay to measure cell activation. J. Immunol. Meth. 94 (1986) 57-63
32. Tsuruga M., Nakajima H., Ozawa S., Togashi M., Chang Y.C., Ando K., and Magae J. Characterization of 4-O-methylascochlorin-induced apoptosis in comparison with typical apoptotic inducers in human leukemia cell lines. Apoptosis 9 (2004) 429-435
33. Nakashima T., Miura M., and Hara M. Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res. 60 (2000) 1229-1235
34. Oveiera A.A., Houchens D.P., and Baker A.D. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann. Clin. Lab. Sci. 8 (1978) 50-56
35. Goldin A., Venditti J.M., Macdonald J.S., Muggia F.M., and Henney J.E. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer 17 (1981) 129-142
36. Sakaguchi K., Nakajima H., Mizuta N., Furukawa C., Ozawa S., Ando K., Chang Y.-C., Yamagishi H., and Magae J. Selective cytotoxicity of acochlorin in ER-negative human breast cancer cell lines. Biochem. Biophys. Res. Commun. 329 (2005) 46-50
37. Tewari M., Quan L.T., O'Rourke K., Desnoyers S., Zeng Z., Beidler D.R., Poirier G.G., Salvesen G.S., and Dixit V.M. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81 (1995) 801-809
38. Segawa H., Kimura S., Kuroda J., Sato K., Nogawa M., Yuasa T., Yokota A., Hodohara K., Fujiyama Y., and Maekawa T. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk. Res. 29 (2005) 451-457
39. Yoshida Y., Moriya A., Kitamura K., Inazu M., Okimoto N., Okazaki Y., and Nakamura T. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J. Bone Miner. Res. 13 (1998) 1011-1022
40. Sasaki A., Kitamura K., Alcalde R.E., Tanaka T., Suzuki A., Etoh Y., and Matsumura T. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int. J. Cancer 77 (1998) 279-285
41. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., and Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J. Bone Miner. Res. 21 (2006) 684-694
42. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., and Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer. Res. 5 (1999) 2223-2229
43. Li Z.L., Abe H., Ueki K., Kumagai K., Araki R., and Ohtsuki Y. Identification of c-Jun as bcl-2 Transcription factor in human uterine endometrium. J. Hist. Cytochem. 51 (2003) 1601-1609
44. Okamoto T., Yamagishi S., Amano S., Takeuchi M., Kikuchi S., Ohno S., and Yoshimura A. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem. Biophys. Res. Commun. 297 (2000) 419-424